Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 6/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP4 | P49662 | 1/20 | 0.35 |
| ▸ | CASP5 | P51878 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922166 | 0.92 | PIK3C3 (0.40) | PIK3C3PRKD1PTPN11SMG1NMT1 | |
| SCHEMBL6927123 | 0.92 | PIK3C3 (0.44) | PIK3C3PRKD1CTSSSMG1NMT1 | |
| SCHEMBL6927160 | 0.91 | DRD2 (0.43) | PIK3C3PRKD1SMG1LRRK2CASP1 | |
| SCHEMBL6925929 | 0.88 | CNR2 (0.46) | MDM2CNR2CASP1CASP4CASP5 | |
| SCHEMBL6928029 | 0.87 | SMG1 (0.43) | PIK3C3PRKD1PTPN11SMG1LRRK2 | |
| SCHEMBL6926804 | 0.87 | TRPA1 (0.39) | PRKD1DRD2DRD4DRD3 | |
| SCHEMBL6925881 | 0.87 | PIK3C3 (0.42) | PIK3C3PTPN11NMT1LRRK2CNR2 | |
| SCHEMBL6924877 | 0.86 | PIK3C3 (0.38) | PIK3C3PRKD1LRRK2CASP1CASP4 | |
| SCHEMBL6928153 | 0.85 | LRRK2 (0.43) | PIK3C3PTPN11LRRK2DRD2DRD4 | |
| SCHEMBL6927498 | 0.85 | ITGB2 (0.41) | PTPN11NMT1LRRK2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | PIK3C3 4567/4885MDM2 4849/4885PRKD1 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.